MED23

Across TCGA pan-cancer cohorts, MED23 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED23 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MED23 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MED23 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BLCA, UCEC, and LUSC are the cancer types where MED23 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.141	0.655	.002	27	view →
UCEC	DFS	Median	All	0.948	0.605	.002	24	view →
LUSC	DFS	Median	All	0.192	0.717	.001	9	view →
LUAD	OS	Median	II,III,IV	0.323	0.712	.006	9	view →
ACC	OS	Median	All	0.217	0.633	.045	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MED23–BLCA (OS)

Open the BLCA breakdown →